Description

(7S,9S)-9-Acetyl-7-[(2S,5R,6S)-5-Amino-6-Methyl-Oxan-2-Yl]Oxy-6,9,11-T Rihydroxy-8,10-Dihydro-7H-Tetracene-5,12-Dione is a structurally complex, high-purity chemical intermediate of significant importance in advanced pharmaceutical synthesis. Its precise stereochemistry and functional groups make it a critical building block for the development of novel therapeutic agents, particularly in the field of oncology. This compound is essential for research institutions, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies engaged in the synthesis of next-generation anthracycline analogs and other specialized active pharmaceutical ingredients (APIs).

Application

• Pharmaceutical Intermediate: Serves as a key chiral precursor in the multi-step synthesis of sophisticated anthracycline-based chemotherapeutic agents.
• Oncology Drug Research: Used in research and development (R&D) for creating new analogs with potentially improved efficacy or reduced side effects.
• API Synthesis: Employed by CDMOs and pharmaceutical manufacturers in the pilot-scale and commercial-scale production of target active pharmaceutical ingredients.
• Biochemical Research: Utilized in academic and industrial laboratories to study structure-activity relationships (SAR) of tetracyclic compounds.
• Process Chemistry Development: Acts as a standard or reference material for developing and optimizing robust, scalable synthetic routes.

Basic Information

Product Name	(7S,9S)-9-Acetyl-7-[(2S,5R,6S)-5-Amino-6-Methyl-Oxan-2-Yl]Oxy-6,9,11-T Rihydroxy-8,10-Dihydro-7H-Tetracene-5,12-Dione
CAS No.	124917-28-8
Molecular Formula	C26H29NO9
Molecular Weight	499.51 g/mol
Synonyms	9-Acetyl-7-[(5-amino-6-methyltetrahydro-2H-pyran-2-yl)oxy]-6,9,11-trihydroxy-8,10-dihydrotetracene-5,12-dione; 7-O-(5-Amino-6-methyltetrahydropyran-2-yl)-9-acetyladriamycinone; A related derivative of Doxorubicin/Adriamycin; Key intermediate for 4'-Iodo-4'-deoxydoxorubicin; Advanced anthracycline synthon.
EINECS	Contact for details

Quality Control

This high-value pharmaceutical intermediate is manufactured under strict quality control protocols to ensure batch-to-batch consistency and purity. Our quality system is designed to meet the stringent requirements of cGMP (Current Good Manufacturing Practice) guidelines for advanced intermediates. A comprehensive Certificate of Analysis (COA) is provided with each batch, detailing purity, identity, and impurity profiles as determined by advanced analytical techniques including HPLC, NMR, and MS.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). This material is light-sensitive (store away from light) and should be handled under an inert atmosphere when appropriate to prevent degradation. Keep the container tightly sealed in a dry environment to minimize exposure to moisture.

Specification

Item	Specification
Appearance	Yellow to orange-red powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Single Maximum Impurity (HPLC)	≤ 1.0%
Total Impurities (HPLC)	≤ 2.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.